FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
February 26, 2021
STOCKHOLM — February 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today a...
YEAR-END REPORT 2020
February 18, 2021